Hatem Soliman - Concepedia

Author

Hatem Soliman

Also Known As

H Soliman, H. H. Soliman, H. Soliman, H.H. Soliman, Hatem H Soliman, Hatem H. Soliman, Hatem Hussein Soliman, Hatem Soliman, Hatem Soliman (523516), Hyo Han

278

Publications

12K

Citations

H-Index

111

Concepts

All Affiliations

Moffitt Cancer Center University of South Florida The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center

About

Hatem Soliman is an author at Moffitt Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	40	5.1K
2	Health Sciences	10	11	2.6K
3	Nursing	4	4	2K
4	Education	1	1	17
5	Natural Sciences	1	1	14

Hatem Soliman

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network NursingSurgical OncologyBreast OncologyCancer ScreeningMedicine	2018	1.6K
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Journal of the National Comprehensive Cancer Network	2020	1.6K
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Meena S. Moran, Jame Abraham, Journal of the National Comprehensive Cancer Network	2022	937
NCCN Guidelines Insights: Breast Cancer, Version 1.2017 William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network Preclinical TherapeuticsEndocrine OncologyRadiation MedicineSurgical OncologyBreast Oncology	2017	538
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Meena S. Moran, Jame Abraham, Journal of the National Comprehensive Cancer Network	2024	419
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 William J. Gradishar, Meena S. Moran, Jame Abraham, Journal of the National Comprehensive Cancer Network Tumor BiologyNccn Guidelines® InsightsBreast OncologyBreast Cancer AddressMedicine	2023	409
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer Álvaro de Mingo Pulido, Alycia Gardner, Shandi Hiebler, Cancer Cell Breast OncologyCancer ImmunosurveillanceMedicineImmunologyImmune Checkpoint Inhibitor	2018	361
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 William J. Gradishar, Meena S. Moran, Jame Abraham, Journal of the National Comprehensive Cancer Network	2021	338
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network Surgical OncologyBreast OncologyHealth SciencesMedicineCancer Management	2016	315
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Clinical Cancer Research	2019	281

Page 1